Investigations on druggable gene mutations related to AML/ALL lineage genes in Advanced Phases of CML: Implications in patient-tailored therapy of blast crisis CML in TKI era

Nawaf Alanazi, Abdulkareem AlGarni, Sarah AlMukhaylid, Maryam AlMajed, Sabreen Alanazi, Muhammad Aamir Khan, Muhammad Farooq Sabar, Mudassar Iqbal, Abid Jameel, Akhtar Hussian, Dhay Almaghlouth, Alhanoof Alsuwaidani, Ghala Basem Alsalem, Nouf AlMutairi, Hassan H Almasoudi, Buthainah AlShehab, Sarah Alfaye, Maryam Butwyibah, Batool Salman Alnajad, Fatimah Hussain Alali, Anwar Hussain Al-Rasasi, Kanza Adeel, Sahar Al-Hakeem, Tarig Karar, Fahad M. Alsaab, Yaqob Samir Taleb, Sana Shahbaz, Sumyiea Riaz Malik, Amer Mahmood, Sulman Basit, Muhammad Anharullah, Aamer Aleem, Irtaza Fatima Zafar, Rizwan Naeem, Masood A. Shamas, Zafar Iqbal
doi: https://doi.org/10.1101/2024.09.08.24313260

Article Information

doi 
https://doi.org/10.1101/2024.09.08.24313260
History 
  • September 9, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Nawaf Alanazi1,3,4,*,
  2. Abdulkareem AlGarni2,3,4,
  3. Sarah AlMukhaylid5,6,*,
  4. Maryam AlMajed6,7,*,
  5. Sabreen Alanazi3,4,*,
  6. Muhammad Aamir Khan8,9,
  7. Muhammad Farooq Sabar8,9,
  8. Mudassar Iqbal8,9,10,
  9. Abid Jameel8,11,
  10. Akhtar Hussian8,12,
  11. Dhay Almaghlouth3,6,*,
  12. Alhanoof Alsuwaidani3,5,6,
  13. Ghala Basem Alsalem3,6,13,
  14. Nouf AlMutairi5,6,
  15. Hassan H Almasoudi14,
  16. Buthainah AlShehab6,7,
  17. Sarah Alfaye3,4,
  18. Maryam Butwyibah3,4,
  19. Batool Salman Alnajad3,4,
  20. Fatimah Hussain Alali3,4,
  21. Anwar Hussain Al-Rasasi3,4,
  22. Kanza Adeel3,4,8,
  23. Sahar Al-Hakeem4,
  24. Tarig Karar3,4,8,15,
  25. Fahad M. Alsaab3,4,8,15,
  26. Yaqob Samir Taleb3,4,8,15,
  27. Sana Shahbaz8,9,
  28. Sumyiea Riaz Malik3,8,16,
  29. Amer Mahmood8,16,
  30. Sulman Basit8,17,
  31. Muhammad Anharullah18,
  32. Aamer Aleem8,16,
  33. Irtaza Fatima Zafar8,19,
  34. Rizwan Naeem20,
  35. Masood A. Shamas8,21 and
  36. Zafar Iqbal3,4,8,9,*,**
  1. 1Division of Hematology/Oncology, Department of Pediatrics, King Abdulaziz Hospital, Al-Ahsa, Saudi Arabia
  2. 2Division of Hematology/Oncology, Department of Medicine, King Abdulaziz Hospital, Al-Ahsa, Saudi Arabia
  3. 3Quality Assurance and Accreditation Unit (QAAA), Genomic & Experimental Medicine Group (GEM), Molecular Oncology/Hematology Section (MoOn-Hem) & & Clinical Laboratory Sciences Program (CLSP), College of Applied Medical Sciences (CoAMS-A), King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS); King Abdullah International Medical Research Centre (KAIMRC) / SSBMT; K ng Abdulaziz Medical City (KAMC), National Guard Health Affairs (NGHA), Al-Ahsa, Saudi Arabia
  4. 4CLSP, COAMS-A, KSAU-HS, Al-Ahsa-Saudi Arabia
  5. 5Johns Hopkins Aramco HealthCare (JHAH), Alahsa, Saudi Arabia
  6. 6Alumni, CLSP, COAMS-A, KSAU-HS, Al-Ahsa-Saudi Arabia
  7. 7School of Biological Science, University of Manchester, Manchester, United Kingdom
  8. 8Hematology, Oncology and Pharmacogenetic-Engineering Sciences Group (H.O.P.E.S.) Pakistan & Pakistan Society for Molecular and Clinical Hematology, Lahore, Pakistan. (www.pak-hematology.org)
  9. 9H.O.P.E.S., Centre for Applied Molecular Biology (CAMB) & School of Biochemistry and Biotechnology (SBB), University of the Punjab, Lahore, Pakistan
  10. 10Asian Medical Institute (ASMI), Kant, Kyrgyzstan
  11. 11Hayatabad Medical Complex, Peshawar, Pakistan
  12. 12Department of Biotechnology, University of Peshawar, Pakistan
  13. 13Almoosa Health Group, Almoosa Specialist Hospital, Al-Ahsa, Saudi Arabia
  14. 14Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Saudi Arabia
  15. 15Department of Basic Medical Sciences, COAMS-A, KSAU-HS, Al-Ahsa-Saudi Arabia
  16. 16College of Medicine & KSU Medical City/King Khalid University Hospital, King Saud University (KSU), Riyadh, Saudi Arabia
  17. 17Center for Genetics and Inherited Diseases, Taibah University, Almadinah Almunwarah, Saudi Arabia
  18. 18National Heart and Lung Institute, Imperial College London, London, United Kingdom
  19. 19Nada International School, Al-Ahsa, Saudi Arabia
  20. 20Director, Molecular Genetic Pathology, Montefiore Medical Centre & Albert Einstein Medical College, New York, USA
  21. 21Department of Oncology, Harvard Medical School, Dana Farbar Cancer Institute, University of Harvard, Boston USA
  1. ↵**Correspondence: Prof. Dr. Zafar Iqbal, drzafar.medgen1{at}gmail.com; iqbalz{at}ksau-hs.edu.sa

  1. ↵* Authors contributed equally and share FIRST AUTHORSHIP.

Back to top
Posted September 09, 2024.
Download PDF
Data/Code
Email
Investigations on druggable gene mutations related to AML/ALL lineage genes in Advanced Phases of CML: Implications in patient-tailored therapy of blast crisis CML in TKI era
Nawaf Alanazi, Abdulkareem AlGarni, Sarah AlMukhaylid, Maryam AlMajed, Sabreen Alanazi, Muhammad Aamir Khan, Muhammad Farooq Sabar, Mudassar Iqbal, Abid Jameel, Akhtar Hussian, Dhay Almaghlouth, Alhanoof Alsuwaidani, Ghala Basem Alsalem, Nouf AlMutairi, Hassan H Almasoudi, Buthainah AlShehab, Sarah Alfaye, Maryam Butwyibah, Batool Salman Alnajad, Fatimah Hussain Alali, Anwar Hussain Al-Rasasi, Kanza Adeel, Sahar Al-Hakeem, Tarig Karar, Fahad M. Alsaab, Yaqob Samir Taleb, Sana Shahbaz, Sumyiea Riaz Malik, Amer Mahmood, Sulman Basit, Muhammad Anharullah, Aamer Aleem, Irtaza Fatima Zafar, Rizwan Naeem, Masood A. Shamas, Zafar Iqbal
medRxiv 2024.09.08.24313260; doi: https://doi.org/10.1101/2024.09.08.24313260
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area